Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Gately, J. O’Flaherty, F. Cappuzzo, R. Pirker, K. Kerr, K. O'Byrne (2011)
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLCJournal of Clinical Pathology, 65
Sreenath Sharma, D. Bell, J. Settleman, D. Haber (2007)
Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 7
K. Nomoto, K. Tsuta, T. Takano, T. Fukui, K. Yokozawa, H. Sakamoto, Teruhiko Yoshida, A. Maeshima, T. Shibata, K. Furuta, Y. Ohe, Y. Matsuno (2006)
Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis.American journal of clinical pathology, 126 4
E. Kwak, Raffaella Sordella, D. Bell, N. Godin-Heymann, R. Okimoto, Brian Brannigan, Patricia Harris, David Driscoll, P. Fidias, T. Lynch, S. Rabindran, J. Mcginnis, A. Wissner, Sreenath Sharma, K. Isselbacher, J. Settleman, D. Haber (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.Proceedings of the National Academy of Sciences of the United States of America, 102 21
J. Marotti, Mary Schwab, N. McNulty, J. Rigas, P. Delong, V. Memoli, G. Tsongalis, V. Padmanabhan (2013)
Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: A retrospective review of 50 casesDiagnostic Cytopathology, 41
M. Milella, C. Nuzzo, E. Bria, I. Sperduti, P. Visca, F. Buttitta, B. Antoniani, R. Merola, A. Gelibter, F. Cuppone, V. D’Alicandro, A. Ceribelli, M. Rinaldi, A. Cianciulli, L. Felicioni, S. Malatesta, A. Marchetti, M. Mottolese, F. Cognetti (2012)
EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with ChemotherapyJournal of Thoracic Oncology, 7
Wen-Hsing Lin, Jen‐Shin Song, T. Lien, Chun‐Yu Chang, Szu-Huei Wu, Yu‐Wen Huang, Teng-Yuan Chang, M. Fang, K. Yen, Chun‐Hwa Chen, Chang-Ying Chu, H. Hsieh, Yi-Rong Chen, Y. Chao, J. Hsu (2012)
A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.Anticancer research, 32 1
J. Bean, Gregory Riely, M. Balak, J. Marks, M. Ladanyi, V. Miller, W. Pao (2008)
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung AdenocarcinomaClinical Cancer Research, 14
W. Pao, Theresa Wang, Gregory Riely, V. Miller, Qiulu Pan, M. Ladanyi, M. Zakowski, R. Heelan, M. Kris, H. Varmus (2005)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2
S. Dacic, Yongli Shuai, S. Yousem, P. Ohori, M. Nikiforova (2010)
Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomasModern Pathology, 23
J. Stamos, M. Sliwkowski, C. Eigenbrot (2002)
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor*The Journal of Biological Chemistry, 277
Jason Smouse, E. Cibas, P. Jänne, V. Joshi, K. Zou, N. Lindeman (2009)
EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancerCancer Cytopathology, 117
A. Kawahara, K. Azuma, A. Sumi, T. Taira, Kazutaka Nakashima, E. Aikawa, H. Abe, Tomohiko Yamaguchi, S. Takamori, J. Akiba, M. Kage (2011)
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.Lung cancer, 74 1
E. Taube, E. Jokinen, P. Koivunen, J. Koivunen (2012)
A novel treatment strategy for EGFR mutant NSCLC with T790M‐mediated acquired resistanceInternational Journal of Cancer, 131
I. García-Olivé, E. Monso, F. Andreo, J. Sanz-Santos, M. Taron, M. Molina-Vila, M. Llatjós, E. Castellà, T. Morán, J. Bertran-Alamillo, C. Mayo-de-las-Casas, C. Queralt, R. Rosell (2009)
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutationsEuropean Respiratory Journal, 35
Daizong Li, L. Ambrogio, L. Ambrogio, T. Shimamura, S. Kubo, Masaya Takahashi, L. Chirieac, R. Padera, G. Shapiro, A. Baum, F. Himmelsbach, W. Rettig, M. Meyerson, M. Meyerson, F. Solca, H. Greulich, H. Greulich, Kwok-kin Wong (2008)
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer modelsOncogene, 27
Susumu Kobayashi, T. Boggon, Tajhal Dayaram, P. Jänne, O. Kocher, M. Meyerson, B. Johnson, M. Eck, D. Tenen, B. Halmos (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 352 8
U. Malapelle, Claudio Bellevicine, P. Zeppa, L. Palombini, G. Troncone (2011)
Cytology‐based gene mutation tests to predict response to anti‐epidermal growth factor receptor therapy: A reviewDiagnostic Cytopathology, 39
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
Shang-Gin Wu, J. Shih, Chong-Jen Yu, Pan‐Chyr Yang (2008)
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 3 4
T. Yung, K. Chan, T. Mok, J. Tong, K. To, Y. Lo (2009)
Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer PatientsClinical Cancer Research, 15
M. Martelli, G. Sozzi, L. Hernández, V. Pettirossi, A. Navarro, D. Conte, P. Gasparini, F. Perrone, P. Modena, U. Pastorino, A. Carbone, A. Fabbri, A. Sidoni, S. Nakamura, M. Gambacorta, P. Fernandez, J. Ramírez, J. Chan, W. Grigioni, E. Campo, S. Pileri, B. Falini (2009)
EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.The American journal of pathology, 174 2
C. Yun, T. Boggon, Yiqun Li, M. Woo, H. Greulich, M. Meyerson, M. Eck (2007)
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.Cancer cell, 11 3
H. Greulich, Tzu-Hsiu Chen, W. Feng, P. Jänne, James Alvarez, M. Zappaterra, Sara Bulmer, D. Frank, W. Hahn, W. Sellers, M. Meyerson (2005)
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLoS Medicine, 2
M. Lewandowska, W. Jóźwicki, B. Żurawski (2013)
KRAS and BRAF Mutation Analysis in Colorectal Adenocarcinoma Specimens with a Low Percentage of Tumor CellsMolecular Diagnosis & Therapy, 17
J. Bean, C. Brennan, J. Shih, Gregory Riely, A. Viale, Lu Wang, D. Chitale, N. Motoi, J. Szőke, S. Broderick, M. Balak, Wen‐Cheng Chang, Chong-Jen Yu, Adi Gazdar, H. Pass, V. Rusch, W. Gerald, Shiu-Feng Huang, Pan‐Chyr Yang, V. Miller, M. Ladanyi, Chih‐Hsin Yang, W. Pao (2007)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 104
A. Smits, J. Kummer, J. Hinrichs, J. Hinrichs, G. Herder, Karen Scheidel-Jacobse, N. Jiwa, T. Ruijter, P. Nooijen, M. Looijen-Salamon, M. Ligtenberg, F. Thunnissen, D. Heideman, R. Weger, R. Weger, A. Vink, A. Vink (2012)
EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinomaCellular Oncology (Dordrecht), 35
A. Pennycuick, T. Simpson, D. Crawley, R. Lal, G. Santis, P. Cane, K. Tobal, J. Spicer (2012)
Routine EGFR and KRAS Mutation analysis using COLD‐PCR in non‐small cell lung cancerInternational Journal of Clinical Practice, 66
Wen-zhao Zhong (2006)
Erlotinib in Lung Cancer - Molecular and Clinical Predictors of OutcomeJournal of Evidence-based Medicine
Tsao (2005)
Erlotinib in lung cancer - molecular and clinical predictors of outcomeN Eng J Med, 353
M. Lewandowska, W. Jóźwicki, Jarosław Starzyński, J. Kowalewski (2012)
Analysis of EGFR mutation frequency and coexistence of KRAS and EGFR mutations using RT-PCR in lung adenocarcinoma: may a clinical and pathological model of a patient’s qualification for targeted therapy have an impact on time to obtain genetic results?, 9
V. Whitehall, K. Tran, A. Umapathy, F. Grieu, C. Hewitt, T. Evans, T. Ismail, W. Li, Peter Collins, P. Ravetto, B. Leggett, M. Salto‐Tellez, R. Soong, S. Fox, R. Scott, A. Dobrovic, B. Iacopetta (2009)
A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting.The Journal of molecular diagnostics : JMD, 11 6
The epidermal growth factor receptor (EGFR) mutation status in the tyrosine kinase domain is known to be a predictor of the response to gefitinib or erlotinib in lung cancer; thus, a non-surgical procedure of tumor specimen collection is critical for mutation analysis. The aim of the present study was to analyze the EGFR, KRAS and BRAF status in limited cytological material. To the best of our knowledge, this is the first time that the quantitative scale of tumor cells and the percentage of tumor cells in cytological material were evaluated at the early stages of pathomorphological material qualification for EGFR, KRAS and BRAF mutation analysis. Our results revealed that even 100-1,000 tumor cells from fine needle aspiration (FNA) samples provided reliable results of mutation analysis when sensitive real-time polymerase chain reaction (PCR) methods were used. EGFR mutations were detected in 10% (7/71) and KRAS mutations were detected in 35% (19/54) of the lung adenocarcinoma cases. In addition, we reported the most common inhibiting mutation (p.T790M) found in coexistence with p.L858R in an FNA sample from a patient, for whom short-term improvement after erlotinib treatment was observed before further progression of the disease. Subsequently, mutual exclusion of EGFR and KRAS mutations was observed. Cytological samples with a small number of tumor cells obtained via FNA, endobronchial ultrasound (EBUS)-transbronchial needle aspiration (TBNA) or brushing are suggested to be used for diagnostic purposes after careful selection by cytopathologists and analysis using a validated, sensitive real-time PCR method.
Oncology Reports – Spandidos Publications
Published: Sep 1, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.